Skip to main content
Equibles

NSRX · Nasus Pharma Ltd

Track NSRX — free

Use NSRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NSRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.40 +0.05 (+1.64%) At close · Sep 11
Rebalance outlook locked
Market Cap
$39.88M
Shares
11.71M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.40 Open$3.50 Day$3.40–3.50 52W close$2.01–9.15 Avg vol 30d14K Short int87K · 0.7% float · 5.9d Short vol11% DataAug 2025–Sep 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-0.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.0%
Year over year · more shares
Price change (1Y)
-58.2%
Trailing year
Short interest
0.7%
Latest settlement · 5.9 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Strong Sentiment Very Bullish Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −21%
below
Price vs 50-day avg −1%
below
RSI (14) 41
neutral
MACD trend Negative
52-week position 20%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +6%
trailing
6-month return +28%
trailing
YTD return −63%
this year
Relative strength +10%
vs S&P · 6-mo
Sentiment
smart money
Very Bullish
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+11% holders QoQ · +4 funds added
Insider flow Accumulating
Net +$20.3K over 90 days · 0% sells
Short interest Falling
0.75% of float · ▼ -39.6% MoM · 5.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
10 holders — near 1-yr high, broad support
Squeeze score 41
elevated · 0–100
Fundamentals
Poor
EPS growth −227%
Y/Y
Free cash flow $-4.9M
Quant / Vol
risk profile
Very High
Volatility 102%
annualized · 1-yr
Max drawdown −78%
past year
ATR 10.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−21% Bearish
Price vs 50-day avg
−1% Neutral
RSI (14)
41 Neutral
MACD trend
Negative Bearish
52-week position
20% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+11% holders QoQ · +4 funds added
Insider flow Accumulating
Net +$20.3K over 90 days · 0% sells
Short interest Falling
0.75% of float · ▼ -39.6% MoM · 5.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
10 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $3 · 20% Range high $9
vs 200-day avg -21% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NSRX
Nasus Pharma Ltd
this stock
$39.88M -62.8% — — 0.7%
LLY
ELI LILLY & Co
 $1.05T +3.8% +44.7% 37.4 0.8%
JNJ
Johnson & Johnson
 $640.02B +28.3% +6.0% 30.9 0.9%
ABBV
AbbVie Inc.
 $454.36B +12.5% +8.6% 72.6 1.1%
MRK
Merck & Co., Inc.
 $355.10B +36.7% +1.3% 115.1 1.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
10
% held
18.4%
Net QoQ
-23.9K sh
Top holder
Balyasny Asset Management…
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
87.3K
Days to cover
5.9d
Change
-57.2K sh
View
Short Volume
Short vol %
11%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
415
Value
$1.4K
As of
Aug 11, 2026
View
Off-Exchange
Off-exchange %
39.8%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$20.3K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$1.2B
Net income (FY)
$-5.9M
EPS diluted
$-0.72
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 4, 2026
This year
15
View
Exempt Offerings
Offering
$15.0M
Filed
Feb 25, 2026
View

Performance

5D 20D 120D MTD YTD
NSRX -9.2% +6.4% +27.5% -16.6% -62.8%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -8.1% +8.2% +9.7% -16.3% -74.9%
Key facts CIK 2029039 CUSIP M7071P109 13F (30d) 6 filings 6 filers Visit website Investor relations